Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat + Surufatinib for advanced neuroendocrine tumors (phase Ib/II)
ChiCTR2200063249Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and surufatinib in apudoma (NET), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
tucidinostatsurufatinib
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on ChiCTR2200063249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063249.